[{"address1": "7 Times Square", "address2": "43rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "929-999-4055", "website": "https://dianthustx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Marino  Garcia M.B.A.", "age": 56, "title": "President, CEO, Secretary & Director", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Savitz", "title": "CFO & Treasurer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward G. Carr", "age": 53, "title": "Chief Accounting Officer", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Judson  Taylor", "title": "Head of Technical Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  Stavenhagen Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Davis Ruff", "title": "VP and Head of Investor Relations & Corporate Affairs.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam M. Veness Esq.", "age": 36, "title": "General Counsel", "yearBorn": 1986, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Maximenko", "title": "Chief People Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Simrat  Randhawa M.B.A., M.D.", "title": "Chief Medical Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rashieda  Gluck", "title": "Head of Clinical Development Operations", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 4, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1701388800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.5, "open": 11.5, "dayLow": 10.54, "dayHigh": 11.53, "regularMarketPreviousClose": 11.5, "regularMarketOpen": 11.5, "regularMarketDayLow": 10.54, "regularMarketDayHigh": 11.53, "payoutRatio": 0.0, "forwardPE": -3.021978, "volume": 21242, "regularMarketVolume": 21242, "averageVolume": 20434, "averageVolume10days": 49170, "averageDailyVolume10Day": 49170, "bid": 0.0, "ask": 0.0, "bidSize": 900, "askSize": 1400, "marketCap": 162995808, "fiftyTwoWeekLow": 0.33, "fiftyTwoWeekHigh": 13.75, "priceToSalesTrailing12Months": 45.992046, "fiftyDayAverage": 10.827, "twoHundredDayAverage": 4.7023, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": -26204618, "profitMargins": 0.0, "floatShares": 5689872, "sharesOutstanding": 14817800, "sharesShort": 19673, "sharesShortPriorMonth": 29874, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0013, "heldPercentInsiders": 0.16525999, "heldPercentInstitutions": 0.68367, "shortRatio": 1.31, "impliedSharesOutstanding": 14817800, "bookValue": 12.038, "priceToBook": 0.91377306, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -43108000, "trailingEps": -2.91, "forwardEps": -3.64, "enterpriseToRevenue": -7.394, "enterpriseToEbitda": 0.571, "52WeekChange": 30.944445, "SandP52WeekChange": 0.24042678, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "DNTH", "underlyingSymbol": "DNTH", "shortName": "Dianthus Therapeutics, Inc.", "longName": "Dianthus Therapeutics, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "1c256785-fa9a-34f5-a846-6abff7f6272e", "messageBoardId": "finmb_631649032", "gmtOffSetMilliseconds": -18000000, "currentPrice": 11.0, "targetHighPrice": 45.0, "targetLowPrice": 23.0, "targetMeanPrice": 30.67, "targetMedianPrice": 24.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 189870000, "totalCashPerShare": 12.814, "ebitda": -45853000, "totalDebt": 670000, "quickRatio": 14.575, "currentRatio": 14.638, "totalRevenue": 3544000, "debtToEquity": 0.376, "revenuePerShare": 0.742, "grossProfits": 6417000, "operatingCashflow": -33858000, "revenueGrowth": -0.212, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -17.055191, "financialCurrency": "USD", "trailingPegRatio": null}]